222 related articles for article (PubMed ID: 31789388)
1. Clinical importance of long non‑coding RNA LINC00460 expression in EGFR‑mutant lung adenocarcinoma.
Nakano Y; Isobe K; Kobayashi H; Kaburaki K; Isshiki T; Sakamoto S; Takai Y; Tochigi N; Mikami T; Iyoda A; Homma S; Kishi K
Int J Oncol; 2020 Jan; 56(1):243-257. PubMed ID: 31789388
[TBL] [Abstract][Full Text] [Related]
2. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
3. Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
Li Y; Zhang N; Zhang L; Song Y; Liu J; Yu J; Yang M
Carcinogenesis; 2020 Sep; 41(9):1195-1202. PubMed ID: 32815538
[TBL] [Abstract][Full Text] [Related]
4. Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy.
Lv P; Yang S; Liu W; Qin H; Tang X; Wu F; Liu Z; Gao H; Liu X
Thorac Cancer; 2020 Jan; 11(1):29-40. PubMed ID: 31691525
[TBL] [Abstract][Full Text] [Related]
5. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
[TBL] [Abstract][Full Text] [Related]
6. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA linc00460 promotes epithelial-mesenchymal transition and cell migration in lung cancer cells.
Li K; Sun D; Gou Q; Ke X; Gong Y; Zuo Y; Zhou JK; Guo C; Xia Z; Liu L; Li Q; Dai L; Peng Y
Cancer Lett; 2018 Apr; 420():80-90. PubMed ID: 29409808
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
[TBL] [Abstract][Full Text] [Related]
10. let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer.
Yin J; Hu W; Pan L; Fu W; Dai L; Jiang Z; Zhang F; Zhao J
Oncol Rep; 2019 Aug; 42(2):495-508. PubMed ID: 31233201
[TBL] [Abstract][Full Text] [Related]
11. LncRNA LINC00460 promotes tumor growth of human lung adenocarcinoma by targeting miR-302c-5p/FOXA1 axis.
Ye JJ; Cheng YL; Deng JJ; Tao WP; Wu L
Gene; 2019 Feb; 685():76-84. PubMed ID: 30359741
[TBL] [Abstract][Full Text] [Related]
12. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
14. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
Bergqvist M; Christensen HN; Wiklund F; Bergström S
Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
[TBL] [Abstract][Full Text] [Related]
15. Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K/Akt signaling.
Zhao H; Wang Y; Ren X
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31123168
[No Abstract] [Full Text] [Related]
16. Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells.
Li F; Cui H; Jin X; Gong X; Wang W; Wang J
Oncol Rep; 2020 May; 43(5):1569-1579. PubMed ID: 32323848
[TBL] [Abstract][Full Text] [Related]
17. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Yue-Yun C; Ye H; Yang F; Qing L; Pan-Pan L; Zhen-Yu D
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2415-2420. PubMed ID: 31450915
[TBL] [Abstract][Full Text] [Related]
18. Decreased human antigen R expression confers resistance to tyrosine kinase inhibitors in epidermal growth factor receptor-mutant lung cancer by inhibiting Bim expression.
Yao Y; Chu H; Wang J; Wang B
Int J Mol Med; 2018 Nov; 42(5):2930-2942. PubMed ID: 30226552
[TBL] [Abstract][Full Text] [Related]
19. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
20. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
